D-Leucine amide-CDDO-Me-HMP
D-Leucine amide-CDDO-Me-HMP is a prodrug composed of CDDO-Me and ligustrazine (HY-N0264). D-Leucine amide-CDDO-Me-HMP can protect against CCl4-induced liver injury. D-Leucine amide-CDDO-Me-HMP can inhibit ROS production, alleviates mitochondrial damage and inhibits cell apoptosis. D-Leucine amide-CDDO-Me-HMP can be used for the research of liver injury[1].
Product Specifications
CAS Number
2749600-16-4
UNSPSC
12352005
Target
Apoptosis; Bcl-2 Family; Caspase; Drug Intermediate; Heme Oxygenase (HO) ; Keap1-Nrf2; Reactive Oxygen Species (ROS)
Related Pathways
Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB; Others
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease
Smiles
[H][C@@]12CC(C)(CC[C@@]1(CC[C@]3([C@@]4(CC[C@]5(C(C)(C(OCC6=CC=C(C=C6)NC([C@@H](CC(C)C)N)=O)=C(C([C@@]5(C4=CC([C@]23[H])=O)C)OCC7=NC(C)=C(N=C7C)C)C#N)C)[H])C)C)C(OC)=O)C
Molecular Formula
C53H73N5O6
Molecular Weight
876.18
References & Citations
[1]Chen F, et al. Development of a leucine aminopeptidase-activatable co-prodrug from CDDO-Me and ligustrazine for synergistic treatment of liver injury. Bioorg Chem. 2025;166:109177.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC740304-100 1x 100 µL
CD106 / VCAM1 (B-K9), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC740040-500 1x 500 µL
CD35 / CR1 (E11), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 